1,3,4-噁二唑,2-(1-甲基乙基)-5-丙基-(9CI) | 138723-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1,3,4-噁二唑,2-(1-甲基乙基)-5-丙基-(9CI)
• 英文名称: 2-n-propyl-5-isopropyl-1,3,4-oxadiazole
• 英文别名: 2-Isopropyl-5-propyl-1,3,4-oxadiazole；2-propan-2-yl-5-propyl-1,3,4-oxadiazole
• CAS: 138723-97-4
• 化学式: C₈H₁₄N₂O
• 分子量: 154.212
• InChiKey: AHFUIKLSBDOXDK-UHFFFAOYSA-N

物化性质

• 沸点：
  228.0±23.0 °C(Predicted)
• 密度：
  0.975±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Butyric acid [2-methyl-prop-(E)-ylidene]-hydrazide 在 sodium acetate 作用下， 以 甲醇 为溶剂， 以58%的产率得到1,3,4-噁二唑,2-(1-甲基乙基)-5-丙基-(9CI)
  参考文献：
  名称：

  Electrooxidative cyclization of N-acylhydrazones of aldehydes and ketones to .DELTA.3-1,3,4-oxadiazolines and 1,3,4-oxadiazoles

  摘要：

  The electrolytic oxidation of ketone N-acylhydrazones (1) in methanolic sodium acetate induced their intramolecular cyclization to the corresponding 2-methoxy-DELTA(3)-1,3,4-oxadiazolines 3. The thermal stability of a given oxadiazoline and what products were formed by its thermal decomposition was found to depend on the natures of the substituents at C-2. Thus, 2-methoxy-2-phenyloxadiazolines preferentially yielded oxiranes 5, whereas 2-alkyl-2-methoxyoxadiazolines preferentially gave enol ethers 6. 2,2-Dimethoxyoxadiazolines decomposed to the parent ketones and many unidentified products. The electrolytic oxidation of aldehyde N-acylhydrazones 2 gave 2,5-disubstituted 1,3,4-oxadiazoles 4. The oxidative cyclization of the N-benzoylhydrazones of aliphatic aldehydes gave especially high yields of the corresponding heterocycles.

  DOI：

  10.1021/jo00031a014

文献信息

• Batch Versus Flow Lithiation–Substitution of 1,3,4‐Oxadiazoles: Exploitation of Unstable Intermediates Using Flow Chemistry
  作者：Jeff Y. F. Wong、John M. Tobin、Filipe Vilela、Graeme Barker

  DOI：10.1002/chem.201902917

  日期：2019.9.20

  isolated yields. Notably, lithiation in batch at room temperature results only in ring fragmentation and we propose that the superior mixing in flow allows interception and exploitation of an unstable intermediate before decomposition can occur.

  1,3,4-恶二唑是药物化学中的常见基序，但是很少有方便的修饰方法。与以前的报道相矛盾的是，在批量和连续流动条件下，使用金属化-亲电捕集技术开发了一种快速，方便，高收率的和一般的1,3,4-恶二唑α-取代的方法，这与以前的报道相矛盾。该环系统导致环断裂。分批地，在工业上方便的温度-30°C下完成锂化，随后的捕集可得到高达91％的分离产率。在连续流动条件下，金属化在室温下进行，随后在流动中进行亲电捕集，得到定量的分离产率。尤其，
• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090156603A1

  公开（公告）日：2009-06-18

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了化学式I的化合物，这些化合物在治疗和/或预防由胰岛素活性不足引起的疾病中非常有用，例如糖尿病。还提供了治疗或预防由胰岛素活性不足或可以通过激活胰岛素来治疗的疾病和疾患的方法。
• HETEROCYCLIC COMPOUNDS
  申请人：SHIONOGI & CO., LTD.

  公开号：US20140249159A1

  公开（公告）日：2014-09-04

  The invention relates to compounds of Formula I: wherein Ar 1 , Ar 2 , Ar 3 , L 1 , L 2 , Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及式I的化合物：其中Ar1，Ar2，Ar3，L1，L2，Y，Z和v在说明书中有定义，以及其药学上可接受的衍生物，包括含有式I的化合物或其药学上可接受的衍生物的有效量的组合物，以及治疗或预防疼痛，尿失禁，溃疡，炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物中给予式I的化合物或其药学上可接受的衍生物的有效量。
• US7897601B2
  申请人：——

  公开号：US7897601B2

  公开（公告）日：2011-03-01